Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Print this page Email this page Users Online: 419
ORIGINAL ARTICLE
Year : 2021  |  Volume : 14  |  Issue : 2  |  Page : 162-165

A Follow-up Study to Evaluate Lipids as Cost-Effective Markers in HIV-Infected Patients on Antiretroviral Therapy


Department of Biochemistry, Armed Forces Medical College, Pune, Maharashtra, India

Correspondence Address:
Pratibha Misra
Department of Biochemistry, Armed Forces Medical College, Pune, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mjdrdypu.mjdrdypu_60_20

Rights and Permissions

Background: Human immunodeficiency virus (HIV) infection per se and antiretroviral therapy (ART) both are associated with dyslipidemias, one of the important risk factors in the development of premature atherosclerosis and coronary artery disease. Certain classes of highly active antiretroviral therapy (HAART), especially protease inhibitors, are more frequently associated with dyslipidemia. The objectives of this study were to evaluate and compare lipid profile – total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglyceride in HIV patients before and after starting ART and also to correlate lipid profile and CD4 counts in HIV infection, thus evaluating the feasibility of using lipid profile to monitor the progression of infection in HIV-infected patients as an adjunct to CD4 counts in resource-limited settings. Methods: Paired samples of 100 newly diagnosed HIV patients were taken before and after treatment with HAART. CD4 cell counts and lipid parameters measured and compared using paired 't'-test. Each of the lipid parameter correlated with CD4 cell count. Results: Significant increase was seen in the levels of TC and HDL-C (P < 0.05) with treatment. CD4 cell count also showed a significant increase (P < 0.05) with therapy. HDL-C levels correlated significantly with CD4 cell counts in pretreatment group (r = 0.23, P = 0.020, 95% C.I.). Conclusion: Combination of zidovudine, lamivudine, and nevirapine is associated with significant increase in HDL-C. HDL-C levels are a good indicator of disease severity in HIV-infected patients before starting the therapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed184    
    Printed0    
    Emailed0    
    PDF Downloaded16    
    Comments [Add]    

Recommend this journal